First liquid biopsy to receive FDA Approval for comprehensive tumor profiling across all solid cancers, Guardant Health’s Guardant360® CDx, gains credibility among oncologists in Asia, Middle East…

The U.S. Food and Drug Administration (FDA) has approved Guardant Health’s liquid biopsy, Guardant360® CDx, for tumor mutation profiling in patients across all solid cancers. For Guardant Health Asia, Middle East and Africa (AMEA), this FDA approval represents a landmark achievement of the Guardant360 test. Currently, the liquid biopsy is commercially available in 41 countries in … Read more